CIPLA MEDPRO REGISTERS TRIOMUNE IN SOUTH AFRICA

A A

Indian generic drug firm Cipla Medpro has registered the antiretroviral drug Triomune in South Africa, the company announced. Triomune contains lamivudine, nevirapine and stavudine -- all part of first-line antiretroviral treatment.

The drug, which will be supplied through local company Enaleni Pharmaceuticals, can help reduce the pill-intake for HIV-positive patients from the current regimen -- six or more tablets per day -- to two tablets per day.

The agreement "is indeed a breakthrough, and represents Cipla's commitment to making life-prolonging medicines accessible and affordable to the broader population," noted Trevor Edwards, CEO of Enaleni Pharmaceuticals.